<?xml version="1.0" ?>
<document id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93">
  <chunk id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0" text="A new Schiff base coordinated copper(II) compound induces apoptosis and inhibits tumor growth in gastric cancer">
    <entity charOffset="6-17" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0.e0" ontology_id="CHEBI_50229" text="Schiff base" type="chemical"/>
    <entity charOffset="30-36" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0.e1" ontology_id="CHEBI_28694" text="copper" type="chemical"/>
    <pair e1="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0.e0" e2="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0.e1" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c0.p0" relation="true"/>
  </chunk>
  <chunk id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1" text="Background: Gastric cancer, as a multifactorial disorders, shows cytological and architectural heterogeneity compared to other gastrointestinal cancers, making it therapeutically challenging. Cisplatin is generally used in clinic for gastric cancer treatment but with toxic side effects and develops resistance. Anti-tumor properties of copper and its coordinated compounds have been explored intensively in recent years.">
    <entity charOffset="192-201" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1.e0" ontology_id="CHEBI_27899" text="Cisplatin" type="chemical"/>
    <entity charOffset="337-343" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1.e1" ontology_id="CHEBI_28694" text="copper" type="chemical"/>
    <pair e1="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1.e0" e2="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1.e1" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c1.p0" relation="true"/>
  </chunk>
  <chunk id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2" text="In this study, we synthesized a novel Schiff base copper coordinated compound (SBCCC) and examined its antitumor effects in two gastric cancer cell lines SGC-7901 and BGC-823 as well as a mouse model of gastric cancer.">
    <entity charOffset="38-49" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2.e0" ontology_id="CHEBI_50229" text="Schiff base" type="chemical"/>
    <entity charOffset="50-56" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2.e1" ontology_id="CHEBI_28694" text="copper" type="chemical"/>
    <pair e1="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2.e0" e2="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2.e1" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c2.p0" relation="true"/>
  </chunk>
  <chunk id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c3" text="The results show that SBCCC can significantly inhibit the proliferation of gastric cancer cells in a dose-and time-dependent manner. The IC50 of SBCCC in SGC-7901 and BGC-823 cells is 1 μM, which is much less than cisplatin's IC50. SBCCC induces apoptosis and causes cell cycle arrest at the G1 phase. SBCCC induces apoptosis via multiple pathways including inhibition of NF-κB, ROS production and autophagy.">
    <entity charOffset="379-382" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c3.e0" ontology_id="CHEBI_26523" text="ROS" type="chemical"/>
  </chunk>
  <chunk id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c4" text="The synthesized SBCCC induced cancer cell death via inhibition of NF-κB, ROS production and autophagy. The multiple cell-killing mechanisms were important to overcome therapeutic failure because of multidrug-resistance of cancer cells. SBCCC, with a lower IC50 compared to cisplatin, could render it the potential to overcome the side-effect for clinical application.">
    <entity charOffset="73-76" id="c5f1d681eb128c9c044a7f5ced6e0e943b201e93.c4.e0" ontology_id="CHEBI_26523" text="ROS" type="chemical"/>
  </chunk>
</document>
